LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 3 | E19 | 72 | hr | 1476 | 1732 | 3694 | 0.4689 | 0.1151 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 1 | D13 | 72 | hr | 1476 | 4004 | 3694 | 1.0839 | 1.1398 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 2 | D13 | 72 | hr | 1476 | 3728 | 3694 | 1.0092 | 1.0153 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 3 | D13 | 72 | hr | 1476 | 1895 | 3694 | 0.5130 | 0.1886 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 1 | M19 | 72 | hr | 1476 | 1804 | 3694 | 0.4884 | 0.1476 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 2 | M19 | 72 | hr | 1476 | 1857 | 3694 | 0.5027 | 0.1715 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 3 | M19 | 72 | hr | 1476 | 1912 | 3694 | 0.5176 | 0.1963 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 1 | H07 | 72 | hr | 1476 | 1333 | 3694 | 0.3609 | -0.0648 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 2 | H07 | 72 | hr | 1476 | 1442 | 3694 | 0.3904 | -0.0157 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 3 | H07 | 72 | hr | 1476 | 1373 | 3694 | 0.3717 | -0.0468 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 1 | C13 | 72 | hr | 1476 | 2727 | 3694 | 0.7382 | 0.5639 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 2 | C13 | 72 | hr | 1476 | 2739 | 3694 | 0.7415 | 0.5693 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 3 | C13 | 72 | hr | 1476 | 2829 | 3694 | 0.7658 | 0.6099 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 1 | D19 | 72 | hr | 1476 | 1463 | 3694 | 0.3960 | -0.0062 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 2 | D19 | 72 | hr | 1476 | 1442 | 3694 | 0.3904 | -0.0157 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 3 | D19 | 72 | hr | 1476 | 1592 | 3694 | 0.4310 | 0.0520 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 1 | N07 | 72 | hr | 1476 | 1517 | 3694 | 0.4107 | 0.0182 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 2 | N07 | 72 | hr | 1476 | 1747 | 3694 | 0.4729 | 0.1219 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 3 | N07 | 72 | hr | 1476 | 1769 | 3694 | 0.4789 | 0.1318 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 1 | O01 | 72 | hr | 1476 | 451 | 3694 | 0.1221 | -0.4626 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 2 | O01 | 72 | hr | 1476 | 630 | 3694 | 0.1705 | -0.3819 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 3 | O01 | 72 | hr | 1476 | 710 | 3694 | 0.1922 | -0.3458 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 1 | O01 | 72 | hr | 1476 | 639 | 3694 | 0.1730 | -0.3778 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 2 | O01 | 72 | hr | 1476 | 763 | 3694 | 0.2066 | -0.3219 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 3 | O01 | 72 | hr | 1476 | 664 | 3694 | 0.1798 | -0.3665 |